Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis. Last reviewed: 21 August 2025 NICE has developed tools and ...

Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617] Awaiting development GID-TA11812 Expected publication date: TBC ...

This guidance will partially update the following: Type 2 diabetes in adults: management (NG28) Status: In progress Developed as: CG Provisional Schedule Draft guidance consultation: 20 August 2025 - ...

Social care We work with the adult and children's care sectors to develop independent recommendations for social care. We develop health and public health advice and guidance, which allows an ...

There is not enough evidence to determine whether price variation is justified between different transcatheter heart valves for transcatheter aortic valve implantation (TAVI) in adults with aortic ...

All NICE products on diet, nutrition and obesity. Includes any guidance, advice and quality standards.

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] In development GID-TA11405 Expected publication date: TBC ...